4521 — KAKEN PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- ¥145bn
- ¥91bn
- ¥77bn
Table: Kaken Pharmaceutical -2024/25 div forecast
Brief: Murakami-Linked City Index Eleventh Raises Joint Stake In Kaken Pharmaceutical To 6.11% From 5.03% - Filing
To Invest About 10 Billion Yen To Build A New Agrochemicals Plant In Shizuoka, Japan
Table: Kaken Pharmaceutical -2023/24 group results
Brief: Eisai: To Divest Rights For Merislon® And Myonal® In Japan To Kaken Pharmaceutical
Table: Kaken Pharmaceutical - 9-MTH group results
Table: Kaken Pharmaceutical - 6-MTH group results
Brief: Silchester Lowers Stake In Kaken Pharmaceutical To 5.9% From 6.95% - Regulatory Filing
Brief: Silchester Lowers Stake In Kaken Pharmaceutical To 6.95% From 8.03% - Regulatory Filing
Table: Kaken Pharmaceutical -Q1 group results
Table: Kaken Pharmaceutical -2022/23 group results
Table: Kaken Pharmaceutical - 9-MTH group results
CymaBay Therapeutics jumps on pricing upsized stock offering at premium
Spruce Biosciences jumps on licensing agreement with Japan's Kaken Pharma
Spruce Bio surges on licensing deal with Japan's Kaken Pharma
Brief: Spruce Biosciences And Kaken Pharmaceutical Announce Strategic Partnership And Exclusive Licensing Agreement To Develop And Commercialize Tildacerfont For Cah In Japan
MediWound rises on approval for burn care drug in Japan
Table: Kaken Pharmaceutical - 6-MTH group results
Table: Kaken Pharmaceutical -Q1 group results